Libertex has added five new contracts for difference (CFDs) to its trading platform. Starting from December, 2018, traders using cross-channel platform will be able to trade with the five hottest instruments, which represent the world’s most popular companies operating in the growing sphere of cannabis production and processing.
CFDs on the following shares are now available with Libertex:
Libertex CEO said: “Cannabis is fast growing sector in Canada and in the US after having recently been legalized for medical and recreational purposes. This has led to a speedy increase in the amount of companies that now grow weed or produce medical products from the plant. Now, an influx in traders seek ways to include these assets into their trading portfolio. We are pleased to be able to satisfy the demand for these financial instruments and add CFDs for the most interesting stocks within the Libertex trading platform.”
Tilray Inc. (ticker – TLRY) is a Canadian medical cannabis producer. It is headquartered in Nanaimo, Canada.
Tilray is one of a select number of licensed companies which are GMP-certified for cultivation, import, release and distribution. It was the first company in the sector to list its shares on the NASDAQ.
Tilray’s shares are traded on the US and Canadian stock markets.
Revenue – Tilray Inc.
According to its 2017 financial results, the company’s income stood at USD 11.4 million. It is projecting a 627% increase (to a total of USD 71.5 million) for financial 2019.
The company was one of the first to supply its products to countries such as Australia, New Zealand, Europe and the US.
Shares and quoted stock prices – Tilray Inc.
The company’s shares are traded on the New York and Toronto stock exchanges. With a unit share price of USD 116, the company’s market capitalization stands at USD 10.18 billion.
Tilray made its IPO on the NASDAQ in August of 2018, at a unit price of USD 23. The company’s shares showed the most growth in September of the same year, rising 1304% to reach USD 300 per share in the space of just two months.
Based on company forecasts predicting increased profits, this period of strong share price growth looks set to continue going forward.
Aurora Cannabis Inc.
Aurora Cannabis (ticker – ACB) is a Canadian medical cannabis producer. It is headquartered in Vancouver, Canada.
Aurora Cannabis is one of a select number of licensed companies which are GMP-certified for cultivation, import, release and distribution. That gives it a considerable competitive advantage in a market with over 400 million potential customers and very few companies which are currently able to meet this demand.
Aurora Cannabis’s shares are traded on the US and Canadian stock markets.
Revenue – Aurora Cannabis
According to its 2017 financial results, the company’s income stood at USD 18.1 million. It is projecting a 205.4% increase (to a total of USD 55.2 million) for financial 2019.
With the growing number of countries passing medical cannabis legislation, the company has adopted an aggressive international expansion strategy. It is currently looking at expanding into Germany, Denmark, Italy and Australia.
Shares and quoted stock prices – Aurora Cannabis
The company’s shares are traded on the New York and Toronto stock exchanges. With a unit share price of USD 6.25, the company’s market capitalization stands at USD 6.23 billion.
In the four years immediately following its IPO in 2014, the company’s share price has risen by 586.8%. That equates to an average of 146.7% per year, which beats any savings account yield hands down.
Canopy Growth Corp
Canopy Growth Corp. (ticker – WEED) is a one of the biggest producers of medical cannabis in Canada, the company was originally known as Tweed Marijuana Inc. before its renaming in September of 2015. It is headquartered in Smiths Falls, Ontario, Canada, having been founded in 2013 by Bruce Linton. By April 2014, it had already been listed. Canopy Growth was the first cannabis producer to be included in stock market indices, currently it operates under numerous brand names, such as Tweed, Bedrocan and Vert Medical.
Revenue – Canopy Growth Corp.
The company’s Q2 2018 results reveal a 33% rise in earnings, which now stand at CAD 23.3 million. Its financial projections for 2019 predict earnings growth of 30%.
Canopy Growth is an industry-leading company and controls over 33% of the cannabis supply in Canada. It has branches in 9 countries around the world, boasting 7 factories and more than 2.4 million square feet of production facilities.
Shares and quoted stock prices –Canopy Growth Corp.
The company’s shares are included in the S&P/TSX Composite index. In May 2018, the company was listed on the New York Stock Exchange (NYSE). Its market capitalization is close to USD 12 billion.
Canopy Growth Corp. has demonstrated cumulative annual growth of approximately 413% over the first 11 months of 2018.
Canopy Growth Corp.’s share price saw a 113.9% increase from August to September 2018, rising from CAD 32.15 to CAD 68.8. Investors who purchased these shares without leverage were able to make a percentage return equal to this amount. If they made use of a leverage (e.g. 1:2), however, they could have increased the size of their return to 227.8%. That really is quite the 1-month rate of return. No savings account yield even comes close to matching it.
Aphria Inc. (ticker – APHA) is a Canadian company specializing in the production, supply and sale of medical cannabis for both the Canadian and international markets. It is headquartered in Leamington, Canada.
Since becoming licensed to produce and sell medical cannabis in 2014, the company’s share price has risen more than ten-fold.
Revenue – Aphria Inc.
According to its 2017 financial results, the company’s income stood at CAD 20.4 million. It is projecting a 987% increase (to a total of CAD 201.3 million) for financial 2019.
Aphria is a major producer of medical cannabis. In 2018, the company completed a series of acquisitions within the sector as part of its strategy to expand into international markets.
Shares and quoted stock prices – Aphria
The company’s shares are traded on the American NYSE and Canadian TSX stock exchanges. With a unit share price of USD 8.83, the company’s market capitalization stands at USD 2.05 billion.
The company is demonstrating revenue growth of over 100% per annum and the industry has massive potential. Over the course of 2017, shares have risen by more than 500% and still have additional growth potential.
Cronos Group Inc.
Cronos Group (ticker – CRON) is a Canadian firm which invests in medical cannabis-producing companies. It is headquartered in Toronto, Canada.
The company owns Peace Naturals (38 ha) and Original BC (12 ha) outright, holding a 21% stake in Whistler Medical Marijuana.
It listed its shares on the NASDAQ (USA) on February 28, 2018.
Cronos Group – Revenue
According to its 2017 financial results, the company’s income stood at USD 4.1 million. It is projecting a 102.4% increase (to a total of USD 8.3 million) for financial 2019.
Cronos Group is a small but fast-growing company operating in a similarly high-speed growth sector.
Shares and quoted prices – Cronos Group
Its shares are traded on the NASDAQ. With a unit share price of USD 8.53, the company’s market capitalization stands at USD 1.52 billion.
Over the 9 months that followed its initial public offering, the company’s share price has increased by 1147% This is one of the best rates of return on the entire American stock market, beating any savings account yield on offer by some margin.